Latest Articles
-
Is An Earnings Beat In The Cards For Merck Stock?
Merck (NYSE: MRK) will report its Q2 2024 results on Tuesday, July 30. We expect the company to post revenue of $15.9 billion and adjusted earnings of $2.20, slightly ahead of the street estimates. As usual, Keytruda will be driving the growth ...
-
With Robust AI Prospects Is IBM A Better Pick Over Merck Stock Within The Dow Index?
We believe that the computing behemoth IBM (NYSE: IBM) is currently a better pick over the pharmaceuticals giant Merck (NYSE: MRK) . The decision to invest often comes down to finding the best stocks within the scope of certain characteristics...
-
Is Johnson & Johnson Stock A Better Pick Over Merck?
We believe that the pharmaceuticals bellwether Johnson & Johnson (NYSE: JNJ) is currently a better pick over its peer Merck (NYSE: MRK) . Although Merck trades at a higher valuation of 5.5x trailing revenues, compared to 4.2 x for J&J,...
-
Is Merck Stock Fully Valued At $130?
Merck (NYSE: MRK) recently reported its Q1 results, with revenues and earnings exceeding our estimates . The company garnered $15.8 billion in revenue and adjusted earnings of $2.07 per share, compared to our estimates of $15.2 billion and $1....
-
Will Higher Keytruda Sales Drive Merck’s Q1
Merck (NYSE: MRK) will report its Q1 2024 results on Thursday, April 25. We expect the company to post revenue of $15.2 billion and adjusted earnings of $1.97, slightly ahead of the street estimates. As usual, Keytruda will be the driving growt...
-
After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
Given its attractive valuation, we believe Pfizer stock (NYSE: PFE) is a better pick than its peer — Merck stock (NYSE: MRK). MRK trades at a higher valuation multiple of 5.6x revenues vs. 2.7x for PFE, due to its superior revenue growth ov...
-
At $100 Does Merck Stock Have Room For Growth?
Merck (NYSE: MRK) reported its Q3 results last month, with revenues and earnings beating the street estimates, and we believe that MRK stock has ample room for growth, as discussed below. The company reported revenue of $16.0 billion and adjus...
-
Should You Pick Merck Stock Over Coca-Cola?
We believe that Merck stock (NYSE: MRK) and Coca-Cola stock (NYSE: KO) will offer little returns in the next three years. Although these companies are from different sectors, we compare them because they have a similar market capitalization...
-
Should You Buy Merck Stock After An Upbeat Q2?
Merck stock (NYSE: MRK), after an 8% fall in a month, underperforming the broader markets, with the S&P500 up 3%, appears to have room for growth. The company posted upbeat Q2 results this week, with solid growth for Keytruda and Gardasil. ...
-
How Has Merck Stock Performed During The 2022-23 Inflation Shock?
Merck stock (NYSE: MRK) currently trades at $110 per share, roughly 43% above its level in March 2021, and it looks fully valued. Merck saw its stock trading at around $91 in late June 2022, just before the Fed started increasing rates, and is ...
-
Is Merck Stock A Better Pick Over ABBV?
We believe that AbbVie stock (NYSE: ABBV) is a better pick than its industry peer, Merck stock (NYSE: MRK). MRK stock trades at a slightly higher valuation of 4.8x trailing revenues, compared to 4.2x for AbbVie, and this valuation gap will ...
-
Should You Buy Merck Stock At $120?
Merck stock (NYSE: MRK) is up 5% in a month, faring slightly better than the broader markets, with the S&P500 up 1%. Although the company posted upbeat Q1 results late last month, we believe MRK stock is fully valued. Merck’s revenue...
-
Earnings Beat In The Cards For Merck Stock?
Merck (NYSE: MRK) will report its Q1 2023 results on Thursday, April 27. We expect MRK stock to trade higher, with its revenue and earnings expected to be above the street estimates. Although the company should benefit from continued market sha...
-
Merck Stock Looks Better Priced Compared To Its Sector Peer
We believe that Merck stock (NYSE: MRK) is currently a better pick than its peer Eli Lilly stock (NYSE: LLY), given its comparatively lower valuation of 4.7x trailing revenues vs. 10.5x for Eli Lilly. Although investors have assigned a high...
-
Here’s What To Expect From Merck’s Q4
Merck (NYSE: MRK) is scheduled to report its Q4 2022 results on Thursday, February 2. We expect MRK stock to trade sideways, with its revenue likely falling slightly below and earnings marginally above the street estimates. Although the company...
